Is Teladoc Stock Really Headed to $220?
Shares of Teladoc Health (NYSE: TDOC) have fallen from post-pandemic peaks this summer, but the company's business hasn't stopped growing at a mind-bending pace. Now that this stock has fallen to a more reasonable valuation, Baird, an investment bank, today gave it an upgrade and a $220 price target that is 18% more than Thursday's closing price.
Analysts have been encouraged by the strong and sustained uptake of Teladoc's services throughout the coronavirus pandemic. Teladoc's network of providers delivered over 2.8 million virtual visits in the third quarter, which was more than three times the number of visits delivered during the prior-year period.
Image source: Getty Images.
Source Fool.com


